Skip to main content

Table 4 Risk of heart failure with DPP-4 inhibitors versus GLP-1 agonists in propensity score matched sensitivity analyses

From: Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

Study population Medications Person-years No. of HF events Crude incidence (per 1000 person-years) Adjusted HR of HF (95% CI)
Primary diagnosis only DPP-4 inhibitors 77,070 3107 40 0.84 (0.80, 0.89)
GLP-1 agonists 70,706 3424 48 Reference
Extend follow-up to 45 days DPP-4 inhibitors 94,201 5714 61 0.89 (0.85, 0.92)
GLP-1 agonists 89,315 6098 68 Reference
  1. CI confidence interval, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, HF heart failure, HR hazard ratio